NEWYORK, NY — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The New York Academy of Sciences will co-host the inaugural PD Therapeutics Conference on Thursday, October 25, in New York City. This meeting is the first and only major scientific symposium exclusively focused on the development of innovative drugs to target Parkinson’s disease.
The conference will bring together academic and industry scientists to assess and discuss how novel scientific advances can be applied to accelerate the development of innovative drug discovery approaches to Parkinson’s disease. Select MJFF-funded investigators will present research on topics including novel neuroprotective agents, innovative mechanisms to address disease symptoms and improvements in relevant animal models, and biomarker discovery/development.
“The PD Therapeutics Conference will feature the latest updates on ongoing research, as well as highlight new studies and concepts,” said conference chair C. Warren Olanow, MD, the Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology and Professor of Neuroscience at the Mount Sinai School of Medicine in New York City, as well as Chief of the Neurology Service at the Mount Sinai Hospital. “Our primary objectives for the conference are twofold: to discuss scientific progress on drug discovery initiatives aimed at better treating Parkinson’s disease, and to provide a new networking opportunity for scientists to share information and resources.”
The conference, targeted toward a multidisciplinary network of academic, pharmaceutical and biotechnology industry researchers, is expected to attract over 100 attendees from around the globe. Due to limited space, registration priority will be given to scientists whose research priority is PD or an allied neuroscience discipline.
The meeting will be held at The New York Academy of Sciences Conference Center, 7 WorldTradeCenter (250 Greenwich St. at Barclay St.), 40th Floor. To register, or for a full conference agenda, visit the NYAS Web site at www.nyas.org/pdconf.
Leadership funding for the PD Therapeutics Conference has been provided by Elan Corporation, plc (NYSE: ELN).